Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Arrien Pharmaceuticals synthesizes MELK and/or FLT3 inhibitors

May 19, 2020

Incyte presents novel PI3K-gamma inhibitors

May 19, 2020

FDA approves Qinlock for fourth-line treatment of advanced GIST

May 18, 2020

FDA grants accelerated approval to Rubraca for BRCA-mutated metastatic CRPC

May 18, 2020

Novartis divulges NLRP3 inhibitors

May 18, 2020

FronThera US Pharmaceuticals synthesizes new TYK2 inhibitors

May 18, 2020

Medshine Discovery discloses Wee1 inhibitors

May 18, 2020

TNFAIP2 identified as potential therapeutic target in platinum-resistant urothelial carcinoma

May 18, 2020

Interim phase II data for apalutamide plus abiraterone acetate/prednisone in prostate cancer

May 18, 2020

First-in-human data for novel proliposomal paclitaxel, TSD-001, in NMIBC

May 18, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...